Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Current Assets (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Current Assets for 12 consecutive years, with $237076.0 as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 36.5% to $237076.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $237076.0, a 36.5% increase, with the full-year FY2025 number at $274628.0, up 91.58% from a year prior.
  • Current Assets was $237076.0 for Q4 2025 at Regen BioPharma, down from $274628.0 in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $994124.0 in Q3 2021 to a low of $62616.0 in Q2 2023.
  • A 5-year average of $281922.1 and a median of $181581.5 in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 863.11% in 2021, then plummeted 85.78% in 2023.
  • Regen BioPharma's Current Assets stood at $641157.0 in 2021, then crashed by 70.13% to $191528.0 in 2022, then decreased by 25.97% to $141795.0 in 2023, then rose by 22.49% to $173683.0 in 2024, then soared by 36.5% to $237076.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Current Assets are $237076.0 (Q4 2025), $274628.0 (Q3 2025), and $179108.0 (Q2 2025).